AllSci News
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
GSK terminates USD 2.2 billion Alector collaboration after back-to-back clinical failures in dementia
GSK terminates Alector collaboration after back-to-back clinical failures in progranulin biology, ending a deal worth up to USD 2.2 billion and leaving the...
Tanabe Pharma exits manufacturing with plant sale to reshape as pure R&D player
Japan-based Towa Pharmaceutical Co., Ltd. (TSE: 4553) has agreed to acquire Tanabe Pharma Factory Co., Ltd., the manufacturing subsidiary of Tanabe Pharma...
Ipsen's Dysport becomes first botulinum toxin to beat placebo in episodic migraine Phase III trial
France-based Ipsen (Euronext: IPN; ADR: IPSEY) reported that abobotulinumtoxinA (Dysport) met primary endpoints in both the E-BEOND and C-BEOND Phase III...
Prime Medicine prevails in Beam dispute, retaining exclusive rights to AATD therapy PM647
An arbitration tribunal has confirmed that Massachusetts-based Prime Medicine (Nasdaq: PRME) holds exclusive development rights over PM647, its investigational prime editing therapy…
FDA expands Octapharma’s Wilate into pediatric von Willebrand disease prophylaxis
The US FDA issued an approval to expand the label of Wilate (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis…
Wugen rebrands as Allotera, raises USD 150m for off-the-shelf CAR-T push
St. Louis-based Allotera Therapeutics, Inc. (formerly Wugen, Inc.) has closed a USD 35 million financing round comprising equity and venture debt, bringing...
Adlai Nortye pushes CEACAM5-targeted Pan-RAS(ON) ADC into first-in-human trial
Adlai Nortye Biopharma, a Taiwan-based oncology company, has initiated a first-in-human clinical trial of AN4035, a bispecific antibody designed to target...
Oryzon secures US patent for LSD1 inhibitor vafidemstat in BPD
Oryzon Genomics (Madrid: ORY), the Barcelona-based epigenetics company, has secured a US Patent (No. 12,673,044) covering methods of treating non-aggressive symptoms of…
Genmab’s Tepkinly wins EC nod as first BsAb regimen for relapsed follicular lymphoma
The European Commission issued a marketing authorization for Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (R²) for relapsed or refractory follicular…
AstraZeneca, Ionis report Phase III failure for eplontersen in ATTR-CM
AstraZeneca (NYSE: AZN) and Ionis Pharmaceuticals (Nasdaq: IONS) reported that eplontersen (Wainua) failed to meet the primary endpoint of the...
Chemomab, Scipher merge in USD 150 million deal to advance AI-guided RA therapy
Israel-based Chemomab Therapeutics (Nasdaq: CMMB) and Burlington, Massachusetts-based Scipher Medicine Corporation have entered into a definitive merger...
CSPC’s B7-H3 ADC wins China breakthrough designation in platinum-resistant ovarian cancer
CSPC Pharmaceutical Group Limited (HKEX: 01093) announced that SYS6043, a humanized monoclonal antibody-drug conjugate (ADC) targeting B7-H3, has been granted Breakthrough Therapy…
Emmecell’s cell therapy wins FDA fast-track designation for corneal endothelial disease
California-based Emmecell announced receipt of US FDA Regenerative Medicine Advanced Therapy (RMAT) designation for EO2002, its investigational allogeneic cultured human corneal endothelial…
Vanda’s antisense therapy wins FDA rare pediatric disease designation for CMT2S
Washington, DC-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the US FDA has granted Rare Pediatric Disease Designation (RPDD) to VCA-894A, an…
The AllSci Brief
Systematic R&D and deal news. Daily.